In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until condition progression or maybe the members are not able to tolerate the study drugs. Ubiquitin-related proteins that control The soundness of essential super enhancer-mediated proteins https://how-does-abbv-744-work-in67912.glifeblog.com/31134548/considerations-to-know-about-abbv-744-brd4-inhibitor-cancer-therapy-efficacy